673 patents currently held
90 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
260
Ending by 2030
Nov 2026
Next term end
378
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2029 · High confidence
Also notable
Ends Dec 2041 · High confidence
Also notable
Ends Mar 2029 · High confidence
Hypotensive Lipid-Containing Biodegradable Intraocular Implants and Related Methods
US 7,799,336
The most cited patent in this portfolio, cited by 274 later US patents, top 5% of utility patents granted in 2010 in our data. Protection runs to 2029.
Treatment of Migraine
US 11,717,515
Cited by 28 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
Method for Detecting Infectious Parvovirus in Pharmaceutical Preparations
US 10,087,493
Cited by 69 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 5 fees due Nov 19 to 26, 2026 · next Nov 19
- 10 fees due Dec 2 to 27, 2026 · next Dec 2
- 15 fees due Jan 7 to 30, 2027 · next Jan 7
- 15 fees due Feb 4 to 28, 2027 · next Feb 4
- 13 fees due Mar 1 to 29, 2027 · next Mar 1
- 9 fees due Apr 6 to 29, 2027 · next Apr 6
- 12 fees due May 3 to 26, 2027 · next May 3
- 8 fees due Jun 1 to 29, 2027 · next Jun 1
- 7 fees due Jul 2 to 26, 2027 · next Jul 2
- 10 fees due Aug 2 to 23, 2027 · next Aug 2
- 15 fees due Sep 8 to 30, 2027 · next Sep 8
- 15 fees due Oct 2 to 28, 2027 · next Oct 2
- 5 fees due Nov 3 to 10, 2027 · next Nov 3
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 48 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 378 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Hyaluronic Acid-Based Gels Including Lidocaine | 13 in force | to Dec 2030 |
| Compositions and Soft Tissue Replacement Methods | 12 in force | to May 2032 |
| Process for Obtaining Botulinum Neurotoxin | 12 in force | to Aug 2030 |
| Biocompatible Structures and Compositions | 11 in force | to Jul 2033 |
| Dermal Filler Compositions Including Antioxidants | 10 in force | to Aug 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,390,829 | ALPHA-2ADRENERGIC Agonists In force · High confidence | In force | High confidence | |
| US 9,149,428 | Processes for Making Cyclic Lipid Implants for Intraocular Use In force · Medium confidence | In force | Medium confidence | |
| US 10,441,543 | Processes for Making Cyclic Lipid Implants for Intraocular Use In force · Low confidence | In force | Low confidence | |
| US 8,877,923 | Substituted 3-(5-Membered Unsaturated HETEROCYCLYL-1, 3-Dihydro-INDOL-2-ONES and Derivatives Thereof as Kinase Inhibitors Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 9,657,005 | Substituted 3-(5-Membered Unsaturated HETEROCYCLYL-1, 3-Dihydro-INDOL-2-ONE'S and Derivatives Thereof as Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,070,808 | Variable Cohesive Gel Form-Stable Breast Implant In force · High confidence | In force | High confidence | |
| US 7,892,565 | Degradable Clostridial Toxins In force · Medium confidence | In force | Medium confidence | |
| US 8,455,535 | Heteroaryl Dihydroindolones as Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,097,644 | Indole Compounds Having SPHINGOSINE-1-Phosphate (S1P) Receptor Antagonist In force · High confidence | In force | High confidence | |
| US 8,206,737 | Hypotensive Lipid-Containing Biodegradable Intraocular Implants and Related Methods In force · High confidence | In force | High confidence |
Also on record, not counted in the 673: 90 patents in force now held by others · 942 patents ended · 68 applications pending · 1,252 applications abandoned · 1 record of undetermined status. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.